Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 856 of 6351
-
New drug duo aims to tackle Transplant-Related lymphoma
Disease control Recruiting nowThis phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who hav…
Phase 2 • Sponsor: Timothy Voorhees • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cell therapy trial aims to halt vision loss in dry AMD
Disease control Recruiting nowThis study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless oth…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced liver cancer: experimental drug TTI-101 enters Mid-Stage trials
Disease control Recruiting nowThe primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine…
Phase 1/2 • Sponsor: Tvardi Therapeutics, Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New eye injection shows promise for blinding swelling condition
Disease control CompletedThis study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New c. diff vaccine shows promise in preventing dangerous diarrhea
Vaccine OngoingAn antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff). Three new formulations of the C. diff vaccine will be use…
Phase 1/2 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC
-
Could this daily pill slow ALS?
Disease control CompletedThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen F will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in participants…
Phase 2/3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cocktail of targeted drugs and chemo takes on pancreatic cancer
Disease control OngoingThis study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:18 UTC
-
Engineered immune cells take on glioblastoma in early trial
Disease control Recruiting nowThe goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Phase 1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a daily pill stop heart attacks in people with hidden artery disease?
Disease control Recruiting nowThe investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preve…
Phase 4 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
A simple care bundle may shield kidneys after major surgery
Disease control OngoingThere is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury. To investigate whether an implementation of a supportive extended care "bundle" in high-risk patients for persistent a…
Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Mpox vaccine shows promise for teens in new study
Vaccine CompletedThis study is a Phase 2 open-label, non-placebo controlled, multi-site clinical trial that will evaluate the standard SC regimen in adolescents ages 12 through 17 years, inclusive, and compared to the standard subcutaneous regimen in adults ages 18 to 50, inclusive. Approximately…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 12:01 UTC
-
New cocktail shows promise for tough head and neck cancer
Disease control CompletedThis is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of camrelizumab in combination with cetuximab and chemotherapy as first-line for patients with relapsed/metastastic head and neck squamous cell carcinoma
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingA prospective, open, randomised implementation study in paediatric cancer patients. The study aims to determine whether a personalised approach will result in an overall reduction in clinically relevant adverse drug reactions (ADRs) and to evaluate the economic and quality of lif…
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for PMR patients: drug may replace long-term steroids
Disease control CompletedThe purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Massive study checks if pneumonia vaccine shields HIV patients
Vaccine CompletedThe purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is s…
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
-
New combo tackles Hard-to-Treat myeloma
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at lea…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Firefighters to help test new Cancer-Detecting blood and urine tests
Knowledge-focused Recruiting nowThis study is an an observational prospective cohort research study to explore the performance of new blood and urine tests for the early detection of cancer among firefighters.
Sponsor: Vincere Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Common painkillers may block colon cancer in high-risk group
Prevention Recruiting nowTo learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
Stroke breakthrough? drug may clear residual clots after standard treatment
Disease control CompletedTECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) proof-of-concept trial evaluating if additional administration of intra-arterial Tenecteplase (TNK) improves reperfusion in patients with incomplete mechanical thrombectomy (MT). For this purpos…
Phase 3 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug shows promise for spine arthritis in chinese patients
Disease control CompletedThe goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat Ankylosing Spondylitis.
Phase 3 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC